Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient

World Journal of Gastroenterology

Volumn 17, Issue 2, 2011, Pages 267-270

  Kim, Sang O ^a   Han, Sang Young ^a   Baek, Yang Hyun ^a   Lee, Sung Wook ^a   Han, Ji Sun ^a   Kim, Byung Geun ^a   Cho, Jin Han ^a   Nam, Kyung Jin ^a  

^a Dong A University College of Medicine   (South Korea)

Author keywords

Adverse effects; Hepatocellular carcinoma; Sorafenib; Splenic infarction; Tyro sine kinase inhibitor

Indexed keywords

ALCOHOL; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; DECARBOXYPROTHROMBIN; FLOXURIDINE; PROTON PUMP INHIBITOR; SORAFENIB; SUCRALFATE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER PATIENT; CASE REPORT; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER CELL CARCINOMA; LOWER ABDOMINAL PAIN; MULTIPLE CYCLE TREATMENT; PROTEIN BLOOD LEVEL; PRURITUS; RECURRENT CANCER; SPLEEN INFARCTION; STOMACH LESION;

EID: 79955783699     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i2.267     Document Type: Article

References (12)

1. Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist 2010; 15: 130-141
2. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, mi-crovascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
4. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96: 1788-1795
5. Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ. Thrombotic events in patients with cancer receiving antian-giogenesis agents. J Clin Oncol 2009; 27: 4865-4873
6. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003; 21: 3542; author reply 3543
7. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 2001; 280: C1375-C1386
8. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002; 100: 4272-4290
9. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010; 28: 2280-2285
10. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevaci-zumab. J Natl Cancer Inst 2007; 99: 1232-1239
11. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrom-botic and Thrombolytic Therapy. Chest 2004; 126: 234S-264S
12. Tran H, Anand SS. Oral antiplatelet therapy in cerebrovas-cular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004; 292: 1867-1874